WHO Approves Essential Medicines for Multiple Sclerosis while Obesity Drugs are Excluded

By Staff Writer

August 10, 2023

The World Health Organization (WHO) has made a significant move in global health by releasing new editions of the Model Lists of Essential Medicines (EML) and Essential Medicines for Children (EMLc). These lists include new medicines for the treatment of multiple sclerosis, cancer, infectious diseases, and cardiovascular conditions among others.

The aim? To increase access to innovative medicines that show clear clinical benefits, without stretching the health budgets of low- and middle-income countries.

With a record 85 applications considered, the updated lists now include a total of 502 medicines on the EML and 361 on the EMLc.

For the first time, medicines for the treatment of Multiple Sclerosis (MS), such as cladribine, glatiramer acetate, and rituximab have been included in the EML. These drugs can delay or slow the progression of MS, offering improved access to treatment for people living with this chronic condition. MS affects approximately 2.8 million people worldwide.
However, it’s important to note that obesity drugs including glucagon-like peptide-1 receptor agonists for weight loss, were not included in the updated EML. This decision is based on the EML’s criteria, which only includes medicines that have solid evidence for safety and efficacy.

Reference url

Recent Posts

mpox outbreak response
     

Mpox Outbreak in Africa: Singapore and Africa CDC Collaborate

🌍 How is international collaboration shaping the fight against the mpox outbreak in Africa?

Discover the latest efforts from Africa CDC and the Ministry of Health, Singapore, to address this pressing health challenge. Their partnership includes critical support such as diagnostic kits and a comprehensive response plan, demonstrating the power of global cooperation in public health. Together, we can enhance diagnostics and strengthen case management to protect the communities most affected.

#SyenzaNews #globalhealth #healthcare #innovation

diabetes prevalence Middle East
          

Rising Diabetes Prevalence in the Middle East and North Africa

🌍 Are you aware of the alarming rise in diabetes cases, particularly in the Middle East and North Africa?

A recent article from the WHO highlights that global diabetes cases have quadrupled since 1990, with nearly 450 million adults going untreated. There’s an urgent need for policy changes and improved health systems to combat this escalating health crisis. Explore the challenges and actions needed to address this significant public health issue.

#SyenzaNews #DiabetesAwareness #GlobalHealth #PublicHealth #MENA

diabetes impact South Africa
       

Diabetes Crisis in South Africa: Prevalence, Impact, and Solutions

🌍 How is diabetes impacting South Africa’s health and economy?

Our latest article looks into the prevalence of diabetes, affecting over 4.2 million adults in the country. With the annual health cost estimated at R2.7 billion, urgent action is needed to combat this crisis. Discover recommended strategies like increasing taxes on sugary beverages and improving early detection efforts.

Learn more about this critical issue and how we can work towards a healthier future for South Africa.

#SyenzaNews #Healthcare #HealthEconomics #PublicHealth #DiabetesAwareness

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2024 Syenza™. All rights reserved.